NCT05119205

Brief Summary

Our study will discuss survival outcomes of multiple myeloma patients admitted on Assiut clinical Hematology and role of neutrophil to lymphocyte and lymphocyte to monocyte ratios as prognostic factors in multiple myeloma.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
64

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2022

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

November 15, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

November 22, 2021

Status Verified

November 1, 2021

Enrollment Period

2 years

First QC Date

November 2, 2021

Last Update Submit

November 14, 2021

Conditions

Multiple Myeloma Survival Outcome

Outcome Measures

Primary Outcomes (1)

  • Determine the survival outcomes of multiple myeloma patients admitted on Assiut clinical Hematology unit

    Survival time will be measured as time from index date (that is, diagnosis date for MM patients) to the date of death; patients without a date of death were assumed alive at the end of the study period. Survival estimates will be assessed by types of treatment among MM patients. In addition, the proportion of patients who died or survived at least 2, 3 or 5 years after diagnosis will be also described.

    2 years

Interventions

Bone marrow biopsy and compete blood countDIAGNOSTIC_TEST

Bone marrow biopsy and compete blood count will be done for follow up in patients with multiple myeloma

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with multiple myeloma in our unit will be included in the study and follow-up will be done to determine the outcome.

You may qualify if:

  • multiple myeloma patients received chemotherapy in our unit.

You may not qualify if:

  • Waldenstrom macroglobulinemia
  • MGUS
  • Amyloidosis
  • Other plasna cell disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assiut University

Study Record Dates

First Submitted

November 2, 2021

First Posted

November 15, 2021

Study Start

January 1, 2022

Primary Completion

January 1, 2024

Study Completion

September 1, 2024

Last Updated

November 22, 2021

Record last verified: 2021-11